| Stefani, Piero Maria |
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 870 | Europe | R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance) | Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum | Mantle Cell Lymphoma | 05/21 | 05/26 | | |
|
| Not yet recruiting | 2 | 56 | Europe | Mosunetuzumab in combination with Zanubrutinib, LUNSUMIO in combination with BRUSINKA | Fondazione Italiana Linfomi - ETS | Follicular Lymphoma | 09/28 | 09/33 | | |
FIL_COLUMN, NCT05249959: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. |
|
|
| Recruiting | 2 | 49 | Europe | Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C)), Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C) | Fondazione Italiana Linfomi - ETS | Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | 04/26 | 04/29 | | |
FIL_POLARDHAP, NCT05966233: R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma |
|
|
| Withdrawn | 2 | 150 | Europe | R-DHAP, Pola-R-DHAP | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent | 01/29 | 01/29 | | |
SilOs, NCT06720870: An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life Context |
|
|
| Recruiting | N/A | 65 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Castleman Disease | 01/25 | 01/25 | | |
NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study. |
|
|
| Recruiting | N/A | 80 | Europe | | Fondazione Italiana Linfomi - ETS | Mantle Cell Lymphoma | 03/25 | 03/25 | | |
FIL_MIMYC, NCT06588205: Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma |
|
|
| Not yet recruiting | N/A | 200 | Europe | | Fondazione Italiana Linfomi - ETS | Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | 12/27 | 12/27 | | |
| Not yet recruiting | N/A | 200 | Europe | | Fondazione Italiana Linfomi - ETS, AIL Roma - Italia, AIL Cuneo - Italia | Plasmablastic Lymphoma | 02/28 | 02/28 | | |
